Cortexyme has added $11.3m to its initial public offering, after the Pfizer, Takeda and Alphabet-based Alzheimer’s therapy developer raised $75m last week.
Cortexyme, the US-based degenerative disease drug developer backed by internet technology conglomerate Alphabet and pharmaceutical firms Pfizer and Takeda, formally closed its initial public offering at approximately $86.3m on Monday.
The company secured $75m last week when it issued more than 4.4 million shares priced in the middle of the IPO’s $16 to $18 range, before the underwriters bought more than 660,000 shares. Its shares closed at $23.90 on Monday.
Founded in 2012, Cortexyme is developing treatments for degenerative…
